Michael R Bubb

Michael R Bubb, M.D.

ASO PROFESSOR

Department: MD-RHEUMATOLOGY
Business Phone: (352) 265-4846
Business Email: bubbmr@ufl.edu

Teaching Profile

Courses Taught
2020
BMS6635 Derm and Msk
2016,2018
MDT7200 Elect Top/Medicine
2018
MDT7090 Elective Topics
2018
BME7980 Research for Doctoral Dissertation
2009-2010
IDH4917 Undergrad Research
2021
PAS5020 Intro to Medicine 2

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Rheumatology
Areas of Interest
  • Osteoarthritis
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

Publications

2022
A clinician’s perspective on why the trial did not work: comment on the editorial by Merrill.
Arthritis & rheumatology (Hoboken, N.J.). 74(6):1092-1093 [DOI] 10.1002/art.42095. [PMID] 35188713.
2021
Egg Consumption and Cardiovascular Risk: Limitations of Observational Data.
The American journal of medicine. 134(8) [DOI] 10.1016/j.amjmed.2021.03.027. [PMID] 34340753.
2021
Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study.
BMC oral health. 21(1) [DOI] 10.1186/s12903-021-01597-x. [PMID] 33964928.
2020
Do Hydroxychloroquine Blood Levels and Dose Identify Different Populations at Risk of Retinopathy? Comment on the Article by Petri et al.
Arthritis & rheumatology (Hoboken, N.J.). 72(12):2165-2166 [DOI] 10.1002/art.41464. [PMID] 32741122.
2020
The Mismatch of Nutrition and Lifestyle Beliefs and Actions Among Physicians: A Wake-Up Call.
American journal of lifestyle medicine. 14(3):304-315 [DOI] 10.1177/1559827619883603. [PMID] 32477033.
2019
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al.
Arthritis & rheumatology (Hoboken, N.J.). 71(8):1391-1392 [DOI] 10.1002/art.40914. [PMID] 31022328.
2018
Does Digital Rectal Examination Reduce Subsequent Hospitalizations and Endoscopies or Vice Versa?
The American journal of medicine. 131(1) [DOI] 10.1016/j.amjmed.2017.08.006. [PMID] 29224615.
2018
Efficacy of Warfarin Anticoagulation and Incident Dementia: Does Cognitive Impairment Reduce Efficacy?
Mayo Clinic proceedings. 93(11) [DOI] 10.1016/j.mayocp.2018.08.019. [PMID] 30392551.
2016
In Reply I-Risk of Disseminated Disease in Immunosuppressed Patients Receiving Live Zoster Vaccine.
Mayo Clinic proceedings. 91(7) [DOI] 10.1016/j.mayocp.2016.04.016. [PMID] 27378041.
2016
Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren’s syndrome.
Journal of immunological methods. 437:28-36 [DOI] 10.1016/j.jim.2016.07.003. [PMID] 27460476.
2016
Sjögren’s syndrome-associated microRNAs in CD14(+) monocytes unveils targeted TGFβ signaling.
Arthritis research & therapy. 18(1) [DOI] 10.1186/s13075-016-0987-0. [PMID] 27142093.
2015
Risk of Disseminated Varicella Zoster in Immunosuppressed Patients Receiving Zoster Vaccination.
Mayo Clinic proceedings. 90(11):1585-6 [DOI] 10.1016/j.mayocp.2015.09.001. [PMID] 26541254.
2013
Anti-Th/To Antibodies in Various Systemic Rheumatic Diseases Screened By Anti-Rpp25 Elisa.
Arthritis and Rheumatism. 65:S287-S288
2013
Biochemical and biophysical properties of a putative hub protein expressed by vaccinia virus.
The Journal of biological chemistry. 288(16):11470-81 [DOI] 10.1074/jbc.M112.442012. [PMID] 23476017.
2012
Clinical Features Associated With Anti-Th/To in Non-Scleroderma Patients – Sine Scleroderma?
Arthritis and Rheumatism. 64:S631-S632
2012
Potential, but unobserved, adverse cardiovascular effects from endurance exercise.
Mayo Clinic proceedings. 87(11):1133; author reply 1133-4 [DOI] 10.1016/j.mayocp.2012.08.011. [PMID] 23127741.
2011
Atypical clinical presentation of a subset of patients with anti-RNA polymerase III–non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Arthritis research & therapy. 13(4) [DOI] 10.1186/ar3422. [PMID] 21781293.
2011
Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.
Arthritis research & therapy. 13(3) [DOI] 10.1186/ar3334. [PMID] 21569292.
2011
Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Clinical rheumatology. 30(10):1333-9 [DOI] 10.1007/s10067-011-1751-0. [PMID] 21523365.
2010
Changes in the Visiting Medical Student Clerkship Program at Mayo Clinic.
Mayo Clinic proceedings. 85(11):1060; author reply 1060-1 [DOI] 10.4065/mcp.2010.0566. [PMID] 21037051.
2010
Identification of a cofilin-like actin-binding site on translationally controlled tumor protein (TCTP).
FEBS letters. 584(23):4756-60 [DOI] 10.1016/j.febslet.2010.10.054. [PMID] 21036172.
2009
Air pollution and life expectancy.
The New England journal of medicine. 360(19):2032-3; author reply 2033 [DOI] 10.1056/NEJMc090375. [PMID] 19420377.
2009
Exogenous thymosin beta4 prevents apoptosis in human intervertebral annulus cells in vitro.
Biotechnic & histochemistry : official publication of the Biological Stain Commission. 84(6):287-94 [DOI] 10.3109/10520290903116884. [PMID] 20055734.
2009
Genetically elevated C-reactive protein and vascular disease.
The New England journal of medicine. 360(9):933-4; author reply 934 [PMID] 19256030.
2009
How depolymerization can promote polymerization: the case of actin and profilin.
BioEssays : news and reviews in molecular, cellular and developmental biology. 31(11):1150-60 [DOI] 10.1002/bies.200900049. [PMID] 19795407.
2008
Clinical Significance of Autoantibodies To Topoisomerase I and Rna Polymerase Iii in An Unselected Rheumatic Disease Population
Arthritis and Rheumatism. 58:S372-S373
2008
Effect of profilin on actin critical concentration: a theoretical analysis.
Biophysical journal. 95(12):5544-73 [DOI] 10.1529/biophysj.108.134569. [PMID] 18835900.
2008
Significant Racial and Gender Differences in Specificity of Scleroderma-Related Autoantibodies
Arthritis and Rheumatism. 58
2008
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients.
Arthritis research & therapy. 10(4) [DOI] 10.1186/ar2493. [PMID] 18759964.
2007
Identification of single and double sites of phosphorylation by ECD FT-ICR/MS in peptides related to the phosphorylation site domain of the myristoylated alanine-rich C kinase protein.
Journal of the American Society for Mass Spectrometry. 18(12):2137-45 [PMID] 17962038.
2007
One-trial in vitro conditioning regulates an association between the beta-thymosin repeat protein Csp24 and actin.
Neuroscience. 148(2):413-20 [PMID] 17681698.
2007
Thymosin beta4: actin regulation and more.
Annals of the New York Academy of Sciences. 1112:76-85 [PMID] 17947588.
2006
A CapG gain-of-function mutant reveals critical structural and functional determinants for actin filament severing.
The EMBO journal. 25(19):4458-67 [PMID] 16977317.
2006
Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.
Arthritis and rheumatism. 54(9):3051-6 [PMID] 16948135.
2006
Profilin: emerging concepts and lingering misconceptions.
Trends in biochemical sciences. 31(4):197-205 [PMID] 16542844.
2006
Tropomodulin 3 binds to actin monomers.
The Journal of biological chemistry. 281(47):36454-65 [PMID] 17012745.
2005
Interactions between vacuolar H+-ATPases and microfilaments in osteoclasts.
Journal of bioenergetics and biomembranes. 37(6):419-23 [PMID] 16691476.
2005
MARCKS is a natively unfolded protein with an inaccessible actin-binding site: evidence for long-range intramolecular interactions.
The Journal of biological chemistry. 280(11):9946-56 [PMID] 15640140.
2004
Actin crystal dynamics: structural implications for F-actin nucleation, polymerization, and branching mediated by the anti-parallel dimer.
Journal of structural biology. 146(3):291-301 [PMID] 15099571.
2004
Effects of profilin and thymosin beta4 on the critical concentration of actin demonstrated in vitro and in cell extracts with a novel direct assay.
The Journal of biological chemistry. 279(32):33519-27 [PMID] 15184365.
2004
Vacuolar H+-ATPase binding to microfilaments: regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actin-binding site in subunit B.
The Journal of biological chemistry. 279(9):7988-98 [PMID] 14662773.
2003
Depolymerization of actin filaments by profilin. Effects of profilin on capping protein function.
The Journal of biological chemistry. 278(27):24629-35 [PMID] 12730212.
2003
Regulation of endothelial nitric oxide synthase by the actin cytoskeleton.
American journal of physiology. Cell physiology. 284(6):C1542-9 [PMID] 12734108.
2003
Thymosin beta 4 interactions.
Vitamins and hormones. 66:297-316 [PMID] 12852258.
2002
Benzo(a)pyrene, but not 2,3,7,8-tetrachlorodibenzo-p-dioxin, alters cell adhesion proteins in human uterine RL95-2 cells.
Biochemical and biophysical research communications. 294(1):101-7 [PMID] 12054747.
2002
Control of actin dynamics by proteins made of beta-thymosin repeats: the actobindin family.
The Journal of biological chemistry. 277(17):14786-92 [PMID] 11856744.
2002
Polylysine induces an antiparallel actin dimer that nucleates filament assembly: crystal structure at 3.5-A resolution.
The Journal of biological chemistry. 277(23):20999-1006 [PMID] 11932258.
2001
Actin filament cross-linking by MARCKS: characterization of two actin-binding sites within the phosphorylation site domain.
The Journal of biological chemistry. 276(25):22351-8 [PMID] 11294839.
2001
Cytoskeletal regulation of the L-arginine/NO pathway in pulmonary artery endothelial cells.
American journal of physiology. Lung cellular and molecular physiology. 280(3):L465-73 [PMID] 11159030.
2001
Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin.
The Journal of biological chemistry. 276(49):45555-63 [PMID] 11579089.
2000
Actin-latrunculin A structure and function. Differential modulation of actin-binding protein function by latrunculin A.
The Journal of biological chemistry. 275(36):28120-7 [PMID] 10859320.
2000
Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations.
The Journal of biological chemistry. 275(7):5163-70 [PMID] 10671562.
1999
Active compression-decompression cardiopulmonary resuscitation.
The New England journal of medicine. 341(23) [PMID] 10610451.
1999
Inclusion body myositis long after dermatomyositis: a report of two cases.
Clinical and experimental rheumatology. 17(2):235-9 [PMID] 10342053.
1999
Lengthening the second stalk of F(1)F(0) ATP synthase in Escherichia coli.
The Journal of biological chemistry. 274(51):36261-6 [PMID] 10593914.
1999
New anti-actin drugs in the study of the organization and function of the actin cytoskeleton.
Microscopy research and technique. 47(1):18-37 [PMID] 10506759.
1999
Phosphorylation-dependent conformational changes induce a switch in the actin-binding function of MARCKS.
The Journal of biological chemistry. 274(51):36472-8 [PMID] 10593944.
1999
Replacement of the aortic root in Marfan’s syndrome.
The New England journal of medicine. 341(19) [PMID] 10577101.
1998
Formation of the b subunit dimer is necessary for interaction with F1-ATPase.
Biochemistry. 37(3):923-32 [PMID] 9454582.
1998
Localization of actobindin, profilin I, profilin II, and phosphatidylinositol-4,5-bisphosphate (PIP2) in Acanthamoeba castellanii.
Cell motility and the cytoskeleton. 39(2):134-46 [PMID] 9484955.
1998
Use of the F-actin-binding drugs, misakinolide A and swinholide A.
Methods in enzymology. 298:26-32 [PMID] 9751868.
1997
Gelsolin activates DNase I in vitro and cystic fibrosis sputum.
Biochemistry. 36(32):9637-41 [PMID] 9289015.
1997
Misakinolide A is a marine macrolide that caps but does not sever filamentous actin.
The Journal of biological chemistry. 272(12):7841-5 [PMID] 9065449.
1997
Profilin interacts with the Gly-Pro-Pro-Pro-Pro-Pro sequences of vasodilator-stimulated phosphoprotein (VASP): implications for actin-based Listeria motility.
Biochemistry. 36(27):8384-92 [PMID] 9204886.
1996
Assembly of MAP-2c and MTBR Fragments into Polymers Resembling Paired Helical Filaments
Journal of Biological Chemistry. 271:32702-32706
1996
In vitro polymerization of embryonic MAP-2c and fragments of the MAP-2 microtubule binding region into structures resembling paired helical filaments.
The Journal of biological chemistry. 271(51):32702-6 [PMID] 8955102.
1996
Self-assembly of the brain MAP-2 microtubule-binding region into polymeric structures resembling Alzheimer filaments.
Biochemical and biophysical research communications. 229(1):176-81 [PMID] 8954102.
1995
Kinetic model for the inhibition of actin polymerization by actobindin.
Biochemistry. 34(12):3921-6 [PMID] 7696256.
1995
Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments.
The Journal of biological chemistry. 270(8):3463-6 [PMID] 7876075.
1994
Actobindin binds with high affinity to a covalently cross-linked actin dimer.
The Journal of biological chemistry. 269(41):25587-91 [PMID] 7929261.
1994
Actobindin induces the accumulation of actin dimers that neither nucleate polymerization nor self-associate.
The Journal of biological chemistry. 269(41):25592-7 [PMID] 7929262.
1994
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.
The Journal of biological chemistry. 269(21):14869-71 [PMID] 8195116.
1993
Rabbit skeletal muscle actin behaves differently than Acanthamoeba actin when added to soluble extracts of Acanthamoeba castellanii.
Biochemical and biophysical research communications. 196(2):569-75 [PMID] 8240329.
1992
Limited proteolysis reveals a structural difference in the globular head domains of dephosphorylated and phosphorylated Acanthamoeba myosin II.
The Journal of biological chemistry. 267(29):20905-8 [PMID] 1400405.
1992
Profilin-actin complexes directly elongate actin filaments at the barbed end.
Biochemistry. 31(6):1827-36 [PMID] 1737036.
1991
Purification of actobindin from Acanthamoeba castellanii.
Methods in enzymology. 196:119-25 [PMID] 1851935.
1991
The interaction of monomeric actin with two binding sites on Acanthamoeba actobindin.
The Journal of biological chemistry. 266(6):3820-6 [PMID] 1995634.
1991
The interfaces of actin and Acanthamoeba actobindin. Identification of a new actin-binding motif.
The Journal of biological chemistry. 266(23):15427-31 [PMID] 1869561.
1990
The covalent structure of Acanthamoeba actobindin.
The Journal of biological chemistry. 265(22):12801-5 [PMID] 2376577.
1973
The isolation of immunogenically pure IgM from Cohn fraction 3 of pooled normal human plasma.
Immunochemistry. 10(2):107-14 [PMID] 4199400.

Grants

Jun 2022 ACTIVE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Role: Principal Investigator
Funding: BIOGEN MA INC
May 2022 ACTIVE
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via ALEXION PHARMACEUTICALS
Dec 2021 ACTIVE
A Phase 1b Randomized, Double-blind, Placebo-controlled, Multiple Ascending-dose Study of EQ001 in Subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
Role: Principal Investigator
Funding: SYNEOS HEALTH via EQUILLIUM
Aug 2021 ACTIVE
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via BRISTOL MYERS SQUIBB CO
May 2021 ACTIVE
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP via UCB BIOPHARMA SRL
Mar 2021 ACTIVE
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AEVI-007 in Subjects with Adult Onset Stills Disease
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via CERECOR
Jan 2021 ACTIVE
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Jun 2020 ACTIVE
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Role: Principal Investigator
Funding: GREENPHIRE via AMGEN INC
Jul 2019 ACTIVE
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via BRISTOL MYERS SQUIBB CO
Apr 2019 ACTIVE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via BRISTOL MYERS SQUIBB CO
Mar 2019 ACTIVE
CTOA Bubb
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Oct 2018 – Oct 2023
A Phase 3, Multicenter, Randomized, Double-Blind, PlaceboControlled,104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with a Single Cycle of Rituximab compared to Belimumab Monotherapy in Adult Subjects with Systemic Lupus Erythematosus (SLE)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via GLAXO SMITHKLINE
Dec 2017 – Nov 2021
A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of Delayed-Release Prednisone (RAYOS?) Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects with Generalized Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: AMPEL BIOSOLUTIONS
Dec 2017 – Dec 2022
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects with Lupus Membranous Nephropathy (LMN)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via GILEAD SCIENCES
Jul 2017 – Jul 2022
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via CELGENE CORP
May 2017 – Nov 2020
A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RSLV-132 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Role: Principal Investigator
Funding: RESOLVE THERAPEUTICS LLC
Feb 2017 – Mar 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis.
Role: Principal Investigator
Funding: IQVIA via HUMAN GENOME SCIENCES
Jun 2016 ACTIVE
CLINICAL TRIAL NETWORK INFRASTRUCTURE GRANT AGREEMENT
Role: Principal Investigator
Funding: LUPUS THERAPEUTICS
Dec 2015 – Feb 2019
Oral Metagenomic Biomarkers in Rheumatoid Arthritis
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Jun 2013 – Nov 2017
BLISS-LN
Role: Principal Investigator
Funding: IQVIA via HUMAN GENOME SCIENCES
Sep 2012 – Dec 2016
Ethnic heterogeneity in microRNA expression as a biomarker in rheumatoid arthritis
Role: Project Manager
Funding: PFIZER INC

Education

Fellowship – Rheumatology
1992 · N I H W G Magnuson
Residency – Internal Medicine
1989 · Barnes Hospital
Medical Degree
1985 · Johns Hopkins University

Contact Details

Phones:
Business:
(352) 265-4846
Emails:
Business:
bubbmr@ufl.edu
Addresses:
Business Mailing:
PO Box 100221
GAINESVILLE FL 32610
Business Street:
CG-97
GAINESVILLE FL 32611